China-based Contract Research Organization (CRO) Biocytogen (Beijing) Co., Ltd has entered into a collaboration with compatriot firm FineImmune. Biocytogen will utilize its self-developed TCR-like antibody technology platform to screen fully human antibody sequences against specific targets and jointly develop innovative cell therapy drugs targeting intracellular tumor-related antigens, combining FineImmune’s unique cell therapy technology platform. Financial details of the deal were not disclosed.
Technology Platforms
Biocytogen boasts the proprietary fully human antibody RenMice platform (RenMab and RenLite Mice), which can be applied to the development of monoclonal and bispecific antibodies. The company has established the TCR-like antibody technology platform, focusing on the discovery of antibodies against intracellular tumor-associated antigens. FineImmune, meanwhile, has developed world-class technology platforms, including a whole genome T cell signal optimization technology platform, TCR high-throughput screening platform, personalized TCR-T cell production technology platform, and T cell efficient delivery system platform (TDP). The company conducts research and development and application of TCR-T, CAR-T, TAL, and TIL cell therapies in renowned cancer hospitals in China, with technologies including individualized tumor antigen-specific TCR-T cell therapy, individualized immunodiagnosis and efficacy evaluation, and individualized precision combination therapy.-Fineline Info & Tech
